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ABSTRACT
Insertional therapies have shown great potential for
combating genetic disease and safer methods
would undoubtedly broaden the variety of possible
illness that can be treated. A major challenge that
remains is reducing the risk of insertional mutagen-
esis due to random insertion by both viral and non-
viral vectors. Targetable nucleases are capable of
inducing double-stranded breaks to enhance homolo-
gous recombination for the introduction of transgenes
at specific sequences. However, off-target DNA cleav-
ages at unknown sites can lead to mutations that
are difficult to detect. Alternatively, the piggyBac
transposase is able perform all of the steps required
for integration; therefore, cells confirmed to contain a
single copy of a targeted transposon, for which its
location is known, are likely to be devoid of aberrant
genomic modifications. We aimed to retarget trans-
poson insertions by comparing a series of novel
hyperactive piggyBac constructs tethered to a
custom transcription activator like effector DNA-
binding domain designed to bind the first intron of
the human CCR5 gene. Multiple targeting strategies
were evaluated using combinations of both plasmid-
DNA and transposase-protein relocalization to the
target sequence. We demonstrated user-defined
directed transposition to the CCR5 genomic safe
harbor and isolated single-copy clones harboring
targeted integrations.
INTRODUCTION
The piggyBac (PB) transposable element can efficiently
integrate transgenes into genomes of mammalian cells
and organisms (1–4). This non-viral vector has several
advantages over integrating viral vectors such as
gamma-retroviral and lentiviral vectors, including low
toxicity, larger cargo size and reduced preference for in-
sertion into actively transcribed genes (5–8). However,
insertional mutagenesis and unknown position effects
that may inhibit transgene expression remain obstacles
for vectors that integrate randomly (9–12). A method
for user-defined directed integration would improve the
safety of insertional therapies.
Engineered nucleases based on transcription activator
like effector (TALE), zinc finger and clustered regularly
interspaced short palindromic repeats (CRISPR)/CRISPR
associated (Cas) systems have been used to induce DSBs
at specific sites (13–17). Subsequent error-prone repair can
leave desired mutations at these sites, and homology-
directed repair can be exploited to introduce a co-de-
livered donor template. Nonetheless, cytotoxicity due to
the cell’s emergency response to DSBs and genotoxicity
resulting from off-target cleavages and mutations remain
concerns for the clinical use of nuclease-based approaches
(15,18–26).
Unlike engineered nucleases, transposons perform all
the enzymatic steps required for integration (27).
Furthermore, we have shown that a chimeric PB
transposase fused to the Gal4 DNA-binding domain
(DBD) can bias integration near endogenous Gal4 recog-
nition sequences (28). We have since modified our vector
architecture to more efficiently localize transpositional
activity and have incorporated a swappable custom
TALE designed to bind a single genomic address.
Genomic safe harbors can be defined as loci that are
well-suited for gene transfer. Integrations within these
sites are not associated with adverse effects such as
proto-oncogene activation or tumor suppressor inactiva-
tion. Furthermore, safe harbors may allow stable trans-
gene expression across multiple cell types. One such
putative site is chemokine C-C motif receptor 5 (CCR5)
(29,30), which is required for the entry of R5 tropic HIV-1
strains involved in primary infections. A homozygous 32
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deletion in the CCR5 gene confers resistance to HIV-1
infection in humans. Disrupted CCR5 expression, natur-
ally occurring in about 1% of the Caucasian population,
does not appear to result in any significant reduction in
immunity (31). Consequently, clinical trials are exploring
the possibility of disrupting CCR5 via targetable nucleases
as part of an anti-HIV therapeutic approach (32).
Here, we introduce novel constructs using a hyperactive
PB transposase coupled with a TALE DBD to target the
first intron of the human CCR5 gene and have detected
stable expression of a reporter gene at this safe harbor. We
identified targeted insertions in 0.010–0.014% of total
stably transfected cells. Furthermore, we demonstrate a
simple PCR-based method for the identification of
targeted clones containing a single transposon. This
‘proof-of-concept’ represents the first example of targeting
an integrating enzyme to a single user-defined TALE-
directed endogenous location. We anticipate that
insights gained from this methodology could someday
improve the safety profile for cell replacement therapies.
MATERIALS AND METHODS
Plasmid development
A detailed description of the construction of PB targeting
plasmids is provided in the Supplementary Materials and
Methods. Simplified illustrations of all PB targeting
plasmids are depicted in Figure 1. All targeting plasmids
were derived from pmhyGENIE-3-R6K (abbreviated
hG3) that encodes a self-inactivating (33,34) hyperactive
PB transposase (35) driven by the CAG [cytomegalovirus
(CMV) immediate early enhancer, chicken b-actin
promoter and b-globin intron] promoter. hG3-TALC1
contains a TALE DBD designed to bind a sequence in
the CCR5 gene (TALC1) directly linked to the PB
transposase. hGT1-TALC1 contains the Gal4 DBD
linked to PB as well as second protein consisting of
Gal4 linked to TALC1. hGT2-TALC1 contains Gal4
linked to TALC1 that was consecutively linked to PB.
hGT3-TALC1 contains TALC1 linked to Gal4 that was
consecutively linked to PB. hG3R1T1-TALC1 contains a
TALE designed to bind a unique sequence in the ROSA26
gene (TALR1) linked to PB as well as TALR1 linked to
TALC1. Four upstream activating sequence (UAS)
arrays, each containing five Gal4 recognition sequences,
were added to the plasmid backbone for hGT1-TALC1,
hGT2-TALC1 and hGT3-TALC1. Four TALR1 recogni-
tion sequences were added to the backbone of hGR1T1-
TALC1. All plasmids feature Gateway recombineering
(Invitrogen) attR sites within the transposon for easy
addition of transgene cargo. The trans-gene was made
by swapping the puromycin gene in pGIPZ (Thermo
Scientific) with a neomycin (GIN) gene amplified from
pERV3 (Agilent Technologies). The fragment including
CMV, TurboGFP, internal ribosomal entry site (IRES)
and GIN was cloned into a pENTR1a shuttle plasmid
(Invitrogen) and subsequently recombined into all target-
ing constructs.
The TALE repeat regions for TALC1, C2 and R1 were
synthesized by BioBasic, Inc. The 16.5-repeat arrays were
cloned by StuI/AatII digestion into pPreTALE (36),
which contained truncated N- and C-termini of the natur-
ally occurring TALE PthXo1 and flanking SfiI restriction
sites. Full binding sites and protein sequences of the SfiI
TALE cassettes are provided in Supplementary Figure S1.
Cell transfections
Human embryonic kidney (HEK293) cells were main-
tained in complete Dulbecco’s modified Eagle’s medium
supplemented with 10% heat inactivated fetal bovine
serum. Before transfection, 2 105 cells per well were
seeded in 12-well plates. Cells at 90% confluency were
transfected with 800 ng of plasmid DNA using X-
tremeGENE 9 (Roche Applied Science). Cells for each
transfection were maintained for 2 weeks under 200 mg/
ml G418 at which point 90% of cells were pelleted and
frozen. Genomic DNA was isolated from pellets using the
DNeasy kit (Qiagen) following the manufacturer’s
protocol. Remaining cells were grown for three additional
days then frozen in liquid nitrogen. A hG3-TALC1 trans-
fection, which was confirmed to contain positive targeted
cells by PCR, was thawed and a dilution of cells was
plated into a 96-well poly-D-lysine coated plate (BD
Biosciences) resulting in 56 colonies per well. After
wells became >40% confluent, the cells were manually
resuspended by pipetting in a total volume of 30 ml. A
volume of 20 ml of the resuspension was removed for
analysis using the DirectPCR Lysis Reagent (Viagen
Biotech), and the remaining cells were cultured further.
A well identified to contain targeted clones was
expanded and single-cell sorted using serial dilution.
Wells were visually monitored and 242 single-cell expan-
sions were obtained. Clonally expanded cells were subse-
quently resuspended by manual pipetting and lysed for
analysis.
Copy number assay
To determine the number of transposons present in
CCR5-targeted single clones, a quantitative PCR copy
number assay was performed as previously described (28).
Flow cytometry
Green fluorescent protein (GFP) expression of 100 000
cells from CCR5-targeted single-cell expansions was
analyzed using a FACSAria III cytometer (BD
Biosciences) after 10 weeks of culture following transfec-
tion with hG3-TALC1.
Colony count assay
The 1 105 HEK293 cells were transfected with equal
molar amounts (maximum 500 ng) of plasmid DNA for
each PB targeting construct in addition to a transposase-
negative control described previously (33). Cells were re-
suspended, diluted 1:100 and plated into 10 cm plates
(1000 total cells per plate) and maintained for 3 weeks
under G418 selection. The fraction of resulting GFP
positive colonies >1mm in diameter were counted using
a FluorVivo 100 fluorescence imaging system (INDEC
Biosystems).
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TALE binding assay
TALE artificial transcription factors were cloned using
XhoI and AgeI, into the PGK promoter-driven mamma-
lian expression vector pPGK-VP64, which appended an
N-terminal HA epitope tag and nuclear localization se-
quence and a C-terminal VP64 transcriptional activation
domain (36). Target sites for the TALEs were cloned
between NotI and XhoI sites upstream of the SV40
promoter in pGL3-control plasmids (Promega).
In 24-well plates, HEK293T cells at 80% confluency in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum, were co-transfected with 100 ng of
TALE expression plasmid, 25 ng of modified pGL3-
control firefly luciferase reporter plasmid containing a
TALE target site and 25 ng of pRL-TK-Renilla
Luciferase plasmid (as a transfection control, Promega),
using Lipofectamine 2000 (Invitrogen). Cells were har-
vested 48 h post-transfection by removing media,
washing with 500ml of 1 phosphate buffered saline
(PBS), followed by lysis in 100ml of 1 Passive Lysis
Buffer (Promega) with 1 Complete protease inhibitors
(Roche). Clarified cell lysates (20 ml) were used to deter-
mine luciferase activity using DualGlo reagents (40 ml,
Promega) in a Veritas microplate luminometer (Turner
Biosystems). All experiments were performed in duplicate
and repeated on two different days.
Targeted genomic integration site recovery
Genomic DNA or DirectPCR lysates (Viagen Biotech)
from stably transfected HEK293 cells were used as
template for nested PCR to identify targeted transposon
insertions. Forward primers were designed to extend
outward from the transposon, whereas reverse primers
were designed to extend from the region adjacent to the
TALC1 recognition sequence (tTTTAGCCTTACTGTT
GA) found uniquely in the first intron of the human
CCR5 gene. Primary PCR products obtained using the
KOD Xtreme Hot Start DNA Polymerase (Novagen)
were diluted 1:50 in H20 and used as template for nested
PCR. Amplification products were gel purified with the
Zymoclean Gel DNA Recovery Kit (Zymo Research)
and cloned into pJet1.2 (Thermo Scientific) for
sequencing. Sequences were aligned to the PB transposon
and human genome using BLAST to identify insertion site
locations. Primer sequences are listed in Supplementary
Table S1.
A hG3-TALC1
E hGR1T1-TALC1
B hGT1-TALC1
C hGT2-TALC1
D hGT3-TALC1
Figure 1. PB targeting plasmids. The TREs flank the PB transposon. The 30TRE resides within an introduced intron in the PB gene leading to
inactivation of the transposase on excision of the transposon. The CAG promoter drives expression of the PB targeting proteins and the IRES allows
for dual expression of two proteins by the promoter. The UAS and R1 recognition sequences for the Gal4 and TALR1 DBDs were engineered into
the plasmid backbones. The transgene can be Gateway recombined between the attR sites. (A) hG3-TALC1 (B) hGT1-TALC1 (C) hGT2-TALC2 (D)
hGT3-TALC1 (E) hGR1T1-TALC1.
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RESULTS
Experimental strategies for targeting PB transposition
Five unique targeting constructs were designed to localize
transposition to the CCR5 locus. hG3-TALC1
(Figure 1A) includes a hyperactive PB transposase with
a protein linker bound directly to a custom TALE DBD
(TALC1) designed to bind a unique 17 bp sequence in the
first intron of the human CCR5 gene (Figure 2A). This
single plasmid includes both the transposon and
transposase and is self-inactivating (33), meaning the
transposase gene is rendered inactive after excision of
the transposon from the plasmid. As a consequence, po-
tentially negative effects that may develop by the persist-
ence of an active PB gene are eliminated. hG3-TALC1 is
analogous to a codon-optimized PB plasmid used to target
insertions near endogenous Gal4 recognition sequences in
the human genome (28).
hGT1-TALC1 (Figure 1B) was designed to include an
additional ‘tethering’ protein on the same bicistronic
coding region as the PB transposase. This plasmid
includes both a Gal4 DBD linked to the CCR5-directed
TALC1, and a Gal4 DBD linked to a hyperactive PB
transposase. Because the backbone of the plasmid
contains twenty UAS sites, the Gal4/TALC1 tethering
protein is expected to bind both the TALE recognition
sequence and the plasmid backbone simultaneously,
thereby localizing the plasmid near CCR5 in the
genome. The Gal4/PB is expected to localize the
transposase to the plasmid backbone via the UAS se-
quences (Figure 2B). We conceived that the additional
flexibility, which may be achieved for this orientation, as
compared with the direct protein fusion used with hG3-
TALC1, would allow for more efficient enzyme activity
after CCR5 localization.
In an effort to simplify the two-protein strategy used for
hGT1-TALC1, two additional constructs were designed to
incorporate both the tethering protein and PB transposase
on a single chain. hGT2-TALC1 (Figure 1C) features
Gal4 linked to the TALC1 DBD that is subsequently
linked to PB. As with hGT1-TALC1, this three-part
molecule could potentially locate the plasmid to CCR5
via the two linked DBDs, Gal4 and TALC1.
Additionally, because PB is also linked to Gal4, there is
a potential for the transposase to be relocated to within
close proximity of the plasmid backbone via the binding of
Gal4 to the UAS sequences (Figure 2C). In a similar
fashion, hGT3-TALC1 (Figure 1D) features the TALC1
DBD at the N-terminal of a three-part molecule linked to
Gal4 that is subsequently linked to PB. The strategy for
targeting for this construct is similar to that of hGT2-
TALC1 except for the locations of two the DBDs are
reversed (Figure 2D).
A modified version of hGT1-TALC1, called hGR1T1-
TALC1 (Figure 1E), incorporates a TALE DBD in place
of Gal4. Because Gal4 has a short 6 bp recognition
sequence, we reasoned that our tethering constructs that
use Gal4 to bind to the plasmid backbone may also be
targeted to the numerous off-target Gal4 recognition se-
quences located in the genome. To prevent this form of
unintended retargeting, we replaced the Gal4 with a
TALE DBD made to bind a specific 17 bp sequence in
the human ROSA26 gene (TALR1) found only once in
the genome. We also replaced the UAS sites on the
backbone with four TALR1 recognition sites so that the
tethering molecule, consisting of TALR1 linked to
TALC1, could bind both the plasmid backbone specific-
ally and the CCR5 locus simultaneously. The purpose of
TALR1 was not to target transposition to ROSA26 but to
increase the specificity of binding of the TALR1/TALC1
double-DBD protein. Similar to hGT1-TALC1, the
transposase was linked to TALR1 so that PB could be
relocated to the plasmid backbone (Figure 2E).
A two-plasmid strategy was devised using hG3-TALC1
combined with a similar plasmid to hGT1-TALC1
described earlier in the text, called hGT1-TALC2, in
which the CCR5 DBD was replaced by an alternative
TALE (TALC2) designed to bind 85 bp upstream of
TALC1. By using different DBDs, we reasoned that the
two strategies could complement one another by allowing
both PB protein (using hG3-TALC1) and plasmid DNA
(using hGT1-TALC2) to locate to neighboring locations
(Figure 2F). Finally, a control plasmid (hG3) was con-
structed containing an unfused hyperactive PB. All con-
structs included a bicistronic CMV promoter driven
TurboGFP and GIN reporter/selection cassette within
the transposon. Successful targeting for all strategies was
expected to result in the excision of the transposon from
the plasmid by the transposase followed by permanent
introduction of the reporter/selection transgenes near the
TALE recognition sequence (Figure 2G).
Activities of PB transposase and TALE
DNA-binding proteins
Integration activities of each PB targeting construct were
compared using a transpositional colony count assay.
Non-integrated plasmid DNA is typically lost due to cell
division after 2 weeks. HEK293 cells were transfected
with each plasmid and grown under G418 selection.
Three weeks later, GFP positive colonies were counted
(Figure 3A). Comparable activities were observed
between transfections for most of the fusion constructs;
however, hGT3-TALC1 had relatively diminished
activity. The unfused PB expressed from hG3 was ap-
proximately twice as active as transposase linked to
Gal4 or TALC1 expressed from fusion constructs. An
average of 111 colonies were counted for the five fusion
constructs on plates each originally seeded with 1000 cells,
thus 11% of total transfected cells received PB integra-
tions. This integration activity is in agreement with
previous hyperactive PB rates in HEK293 cells (37) and
represents a 26-fold increase in activity over random inte-
gration by a transposase-negative control.
Binding activity of the three TALEs used in this study
was verified using a transcription factor reporter assay
(Figure 3B). We constructed expression plasmids append-
ing a VP64 transcriptional activation domain to TALC1,
TALC2 or TALR1. Reporter (Rep) plasmids were each
designed to contain a single TALE-binding site located
upstream of a minimal promoter driving luciferase (Rep
C1, Rep C2, Rep R1). Control cotransfections of
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A B
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E F
G
hG3-
TALC1
hGT1-
TALC1
hGT2-
TALC1
hGT3-
TALC1
hGR1T1-
TALC1
hGT1-
TALC2
+
hG3-
TALC1
Figure 2. Schematic for various PB targeting strategies. For each strategy, all components are encoded on a single plasmid, and most components
have been omitted for simplification purposes from plasmids depicted in this figure. (A) hG3-TALC1 encodes a hyperactive PB transposase cova-
lently linked to a TALE designed to bind a specific sequence in the CCR5 gene (TALC1). (B) hGT1-TALC1 encodes a double-DBD protein
including TALC1 linked to Gal4. Tethering of the plasmid to CCR5 is mediated by Gal4 binding to UAS sites found on the plasmid backbone and
TALC1 binding to the genomic recognition sequence. Additionally, hGT1-TALC1 encodes a Gal4-PB fusion to draw PB to the plasmid. (C) hGT2-
TALC1 encodes a three-part protein consisting of Gal4 linked to TALC1 followed by the PB transposase. Tethering of the plasmid to the CCR5
genomic sequence is made possible by the TALE and Gal4 segment of the protein through binding of Gal4 to UAS sites found on the plasmid
backbone. In addition, PB can be relocated to CCR5 via direct linkage to TALC1. (D) hGT3-TALC1 is similar to hGT2-TALC1 except for the
TALE and Gal4 DBDs are reversed. Similar to hGT2-TALC1, the TALE and Gal4 segment of the three-part protein mediates the relocation of the
plasmid to CCR5. PB is directly linked to the duel DBDs and can therefore also be relocated to the site of interest. (E) hGR1T1-TALC1 encodes a
double-DBD including TALC1 linked to a second TALE (TALR1) made to bind specific recognition sites introduced into the plasmid backbone.
The double-DBD can therefore simultaneously bind the plasmid and CCR5. hGR1T1-TALC1 also encodes PB linked to TALR1 for the relocation
of the transposase to the plasmid backbone and consequently to CCR5. (F) hGT1-TALC1 was modified by replacing TALC1 with a TALE made to
bind upstream of TALC1 in the CCR5 gene (TALC2) to make hGT1-TALC2. By combining hG3-TALC1 and hGT1-TALC2 plasmids in a single
transfection, both plasmid DNA retargeting and transposase retargeting strategies were used simultaneously to enhance transposition near CCR5.
(G) The TALE-localized PB is expected to excise the transposon containing the reporter transgene GFP IRES neomycin (GIN) from the targeting
plasmid and integrate nearby. Red arrows indicate PCR primers used to assay for targeted insertion. The depicted genomic primer CCR5 Rev is
located 761 bp from the TALC1 recognition site.
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expression and reporter plasmids with unmatched TALE
activator and target sequences resulted in background
levels of luciferase activity. Cotransfection with the
cognate TALE-activator and Rep C1, Rep C2, Rep R1
plasmids led to a 9, 12 and 23-fold induction of luciferase,
respectively, confirming that the custom TALEs were
binding and specific for their target sequence.
PB constructs mediate TALE-directed transposition to the
CCR5 locus
We tested the hypothesis that our TALE-tethered PB con-
structs could guide transposition to regions adjacent to the
TALC1 recognition site found in the CCR5 safe harbor
locus. Six independent transfections for each PB targeting
construct were performed and cells were subsequently
selected with G418 antibiotic for 2 weeks. To estimate
whether a given polyclonal population was likely to
contain a high percentage of targeted clones, an initial
PCR screen was performed using direct primers designed
to extend from the transposon and complementary
primers made to extend from the genomic CCR5
sequence. Amplification products arising from both
primers included the flanking terminal repeat element
(TRE) of the transposon followed by the PB canonical
TTAA junction and genomic sequence of CCR5
(Figures 2G and 4A). A total of 14 unique insertion sites
within CCR5 were recovered. Four of the six transfections
with hG3-TALC1 gave rise to targeted insertions
including one transfection resulting in two independent
insertions. Two transfections each for hGT1-TALC1 and
hGR1T1-TALC1 and a single transfection from hG3T3-
TALC1 resulted in positive insertions. The transfections
with both hG3-TALC1 and hGT1-TALC2 in combin-
ation gave rise to four insertions. No insertions were re-
covered from hGT2-TALC1 or hG3 control transfections
(Table 1).
Two of the observed insertion sites were recovered from
multiple transfections. One site, located 24 bp upstream of
the TALC1 recognition sequence, was recovered from two
independent hG3-TALC1 transfections as well as from
hGT1-TALC1 and hGR1T1-TALC1 transfections.
Additionally, one site, located 221 bp upstream of the
TALC1 sequence, was targeted by both hG3-TALC1
and hGT3-TALC1. In all, 9 of the 14 insertion sites
were located within 250 bp of the TALC1 sequence, and
two insertions were located 639 and 659 bp away. In
addition, three insertions at distances of 1231, 3495 and
3991 bp were recovered far from the target sequence.
(Figure 4B and Table 1). This represents the first
evidence that an integrating enzyme can be made to
target a transgene to a genomic location using a user-
defined TALE.
Isolation of CCR5 targeted clones
Successful cell replacement therapy using this approach
will require that rare targeted clones be identified from
the original polyclonal transfection for subsequent use.
hG3-TALC1 gave rise to the highest number of insertions
as analyzed by our initial screen (Table1); therefore, we
chose a single polyclonal population that produced one of
these insertions to attempt to identify and clonally expand
safely modified cells.
Cells originating from a hG3-TALC1 transfection were
plated into a single 96-well plate. One week later, each
well was found to contain an average of 56 colonies
(Figure 5A). Each well was resuspended, and a fraction
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Figure 3. Verification of transposase and TALE activity. (A)
Comparison of integration efficiencies between PB constructs trans-
fected into HEK293 cells. One thousand cells were plated and
cultured for 3 weeks before G418 resistant/GFP+ colonies were
counted. Data are shown as mean values with SD (n=3). (B)
Binding activity of TALE proteins was determined using a transcription
factor reporter activation assay in HEK293 cells. TALC1, TALC2 and
TALR1 activators were each assayed on luciferase reporter plasmids
Rep C1, Rep C2 and Rep R1, which carried a single target site for each
TALE activator (n=4).
A
TCTTTCTAGGGTTAAGATAATCAGAATTTTCTTAACCTTTTA
a1 a2,d1
a3,a4,b1,e1
a5b2
e2
f1
f2 f3 f4
CCR5
TALC1B
Figure 4. (A) Chromatogram and sequence of PCR product recovered
from a representative hG3-TALC1 transfection showing the PB TRE
on the left in bold, TTAA junction and flanking genomic CCR5
sequence on the right. (B) Locations of insertion sites recovered in
the CCR5 gene. a, hG3-TALC1; b, hGT1-TALC1; c, hGT2-TALC1
(no insertions); d, hGT3-TALC1; e, hGR1T1-TALC1; f, hG3-
TALC1+hGT1-TALC2; g, hG3 (no insertions).
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of the cells were removed and lysed for direct PCR
analysis. Using an identical PCR as the initial screen, a
positive well was identified to have the same insertion as
previously obtained that was located 24 bp upstream from
the TALC1 recognition sequence. In a final step, this
positive well was single-cell sorted and direct lysis tem-
plates from 242 single-cell expansions were screened by
PCR. A total of five wells (2%) were verified to have
targeted insertions. This frequency of 1/48 positive wells
parallels the expected frequency of 1/56 positive colonies
from which the single-cell expansions arose. Lysates from
20 clonal expansions isolated from a control hG3 trans-
fection did not give rise to PCR products (Figure 5B).
Two positive clones (293-1 and 293-2) were expanded
for further analysis. A quantitative PCR copy number
assay revealed that both clones contained a single trans-
poson insertion (Figure 5C). Position effects caused by
neighboring CCR5 genomic sequences could lead to
silencing of the transgene. As analyzed by flow cytometry,
robust GFP expression from targeted clones was detected
beyond 10 weeks of culture (Figure 5D). Populations
expanded from clones 293-1 and 293-2 were found to be
99.9 and 98.0% GFP positive, respectively.
Targeting efficiencies of hG3-TALC1 and hGT1-TALC1
An initial PCR screen was used to estimate the relative
targeting efficiencies of the five TALC1-directed PB con-
structs (Table 1). The two most promising constructs,
hG3-TALC1 and hGT1-TALC1, resulted in more than
one insertion within 250 bp of the TALC1 genomic recog-
nition site. As described earlier in the text, hG3-TALC1
transfection #1 was plated into wells on a 96-well plate
and a single well containing a targeted colony was
identified. Each well contained an average of 56 colonies;
therefore, we identified about one in 5376 correctly
modified cells. This represents 0.019% of total stably
transfected cells. To gain a better understanding of the
number of targeted cells present in our polyclonal popu-
lations, cells originating from a single hGT1-TALC1
transfection and two hG3-TALC1 transfections were
seeded into additional wells. The hGT1-TALC1 transfec-
tion #1 was plated into 960 wells, and an average of eleven
colonies per well was counted. hG3-TALC1 transfections
#1 and #2 were each plated into 480 wells, and averages of
16 colonies per well were counted. A single positive well
was identified by PCR for all three transfections. By
including the data from the first plating of hG3-TALC1
transfection #1, we determined that the percentage of
targeted cells found for hG3-TALC1 transfections #1
and #2 was 0.015 and 0.013, respectively, or 0.014
combined. The hGT1-TALC1 transfection resulted in
0.010% of targeted cells (Table 2).
DISCUSSION
The ability of viruses to efficiently introduce therapeutic
transgenes permanently into cellular chromosomes has led
to reliable treatments for a diverse set of genetic diseases
(38). A system that could safely direct insertions to
genomic safe harbors would overcome the strong prefer-
ence for the disruption of active genes that burdens viral-
based approaches (5,7,8), thereby transforming the gene
therapy field.
In an effort to reduce the risks of random viral insertion,
Papapetrou et al. (39) has defined criteria for de novo safe
harbor sequences in the genome based on their position
relative to contiguous coding genes, microRNAs and
ultraconserved regions. This strategy involves clonally ex-
panding cells containing random integrations followed by
identifying all genomic insertion sites. Only clones contain-
ing a single insertion that is located within these ‘safe’
regions are selected. This strategy does not require screening
for insertions at specific sites, which may reduce the neces-
sary number of clones. Drawbacks include the requirement
for the identification of random insertion sites in the genome
for each clone as well as ambiguity about the selected safe
harbor. These de novo safe harbor sequences may perform
unidentified cellular functions and local chromosomal
Table 1. Transposon insertions recovered in CCR5
Construct Insertion site # Transfection Distance to
TALC1 (bp)
Transposon
orientation
Flanking CCR5 sequence
hG3-TALC1 a1 #2 1231 For TTAATCAATGCCTT
a2 #3 221 For TTAAAACTCTTTAG
a3 #1 24 For TTAAGATAATCAGA
a4 #4 24 For TTAAGATAATCAGA
a5 #2 639 For TTAAAGGGAGCAA
hGT1-TALC1 b1 #5 24 Rev TTAAGATAATCAGA
b2 #1 236 Rev TTAAGCTCAACTTA
hGT2-TALC1 c0
hGT3-TALC1 d1 #3 221 Rev TTAAAACTCTTTAG
hGR1T1-TALC1 e1 #5 24 For TTAAGATAATCAGA
e2 #1 3495 For TTAAAAGGAAGTTA
hG3-TALC1+hGT1-TALC2 f1 #4 37 For TTAATAGCAACTCT
f2 #6 247 Rev TTAAAAGGAAGAAC
f3 #5 659 For TTAATAACTAACAA
f4 #3 3991 For TTAAATGAGAAGGA
hG3 g0
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position effects at these sites are unknown. These issues
may necessitate individual characterization of each clone
and are likely to be resolved by targeting a specific well-
characterized safe harbor.
In an attempt to redirect viral insertions to a known
sequence, an HIV integrase fused to a zinc finger,
designed to bind the erbB-2 gene, has been shown to
increase targeted integration into the genome by 10-fold
compared with wild-type HIV integrase (40). A non-viral
alternative approach has been to use zinc-finger recombin-
ases (ZFRs) consisting of a custom designed zinc-finger
DBD and recombinase catalytic domain. Insertion site
preference can be altered by zinc-finger binding but is re-
stricted by sequence requirements dictated by the native
recombinase. Using directed evolution, unique catalytic
domains have been produced that are able to tolerate add-
itional core sequences, theoretically allowing ZFRs to
target up to 3.77 107 unique genomic sites (41). ZFRs
display high targeting efficiencies (8.3–14.2%) of stably
transfected cells but are limited by target site inflexibility
and low total integration efficiencies (0.14–0.31%).
Targetable transposition, using chimeric proteins con-
sisting of a DBD fused to a transposase, can be used to
preferentially insert transgenes near a specific sequence. A
variety of DBDs have been used to bias transposon inte-
gration on recipient plasmids in various cell types (28,42–
49). Recently, endogenous transpositional targeting has
been achieved (28,42). The Rep DBD, known to target
the wild-type adeno-associated virus (AAV) to a region
on human chromosome 19 called AAVS1, was used to
bias integrations of PB, Sleeping Beauty and Tol2 trans-
posons near both minimal Rep binding sequences (15 726
sites per human genome) and consensus Rep binding se-
quences (2134 sites per human genome) (42). Previously,
we demonstrated that a Gal4-PB transposase fusion was
able to bias 24% of integrations near endogenous Gal4
recognition sequences; however, these targets were found
in numerous genomic locations and, like the Rep DBD, its
recognition sequence was pre-defined (28). Moreover, in
our preliminary study, single targeted clones were not
isolated. Here, we have evaluated the ability of a variety
of vector architectures to localize transposition near a
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Figure 5. (A) Cells from a hG3-TALC1 transfection were plated into a 96-well plate, and 1 week later, individual non-overlapping colonies were
established for counting; 40 magnification. (B) Nested PCR for the identification of transposition near CCR5. Expected products arose from five
positive clones identified from hG3-TALC1 transfection, but not clones from hG3 control transfection. The asterisk denotes a sequenced non-specific
PCR product. (C) Transposon copy number for clones 293-1 and 293-2. Quantitative PCR predictions were calibrated using a reference HEK293 cell
line known to contain a single copy transposon. (D) Cells positive for GFP reporter gene targeting to CCR5 displayed sustained expression past 10
weeks of culture. Flow cytometry analysis displaying GFP positive events for both untransfected HEK293 cells and an expansion of clone 293–1.
Table 2. Targeted cells recovered from hG3-TALC1 and hGT1-TALC1
Construct hG3-TALC1 #1 hG3-TALC1 #2 hG3-TALC1 combined hGT1-TALC1 #1
Total cells screened 13 686 7622 21 308 10 476
Positive wells 2 1 3 1
% Targeted cells 0.015 0.013 0.014 0.010
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user-defined TALE recognition sequence found in the
CCR5 gene. TALEs are simple to generate and can be
designed to specifically bind almost any sequence (50).
By fusing a TALE to the PB transposase using a direct
protein linker (hG3-TALC1 and hGT3-TALC1) or by
tethering the TALE to the plasmid backbone (hGT1-
TALC1, hGT3-TALC1 and hGR1T1-TALC1), or by
combining both strategies (hG3-TALC1+hGT1-
TALC2), we achieved user-defined directed integration
into the genome. We targeted an endogenous genomic
safe harbor and recovered multiple insertion sites within
this region ranging from 24 to 3991 bp near the TALE
recognition sequence. Two ‘hot-spots’, 24 and 221 bp
away, were targeted multiple times and most insertions
(9/14) clustered within 250 bp of the TALE sequence.
Rare targeted clones positive for a single CCR5-targeted
insertion were isolated and stable GFP reporter expression
was confirmed for these cells.
The aim of these experiments was to demonstrate the
ability of our novel PB constructs to target a user-defined
genomic address. Although we did successfully obtain
targeted integrants, these primary experiments necessitate
a number of improvements to the system. After transfec-
tion with our TALE-directed PB construct, we performed
a simple pre-plating step into a single 96-well plate
followed by PCR analysis. This allowed for the isolation
of a small pool (56 colonies) of potentially targeted cells
before single-cell sorting. Although we were successful in
identifying positive single-cell expansions in 1/48 (2%) of
wells, it would be desirable to omit the pre-screening step
used in these experiments. Although we were able to
identify targeted insertion sites for all constructs except
hGT2-TALC1, many transfection replicates did not give
rise to detectable insertions (Table 1). It is likely that these
polyclonal populations contained additional targeted in-
sertions; however, the percentage of targeted cells was low
and therefore was not detectable by our PCR screen.
Moreover, the targeting efficiencies of total stably trans-
fected cells observed for our constructs were 0.010–
0.014%, which are significantly lower than nuclease-
based approaches used to target CCR5 (51). These
efficiencies might be improved by performing additional
experiments aimed at optimizing transposase expression
level by assaying a range of transfection concentrations.
The hyperactive pB transposase is exceptionally efficient
at integration (35,37) and does not rely on rate-limiting
host-factors, as do alternative retargeting strategies. This
system, currently in early stages, is ideally suited for
improvements to efficiency.
The PB transposase is autonomously functional in our
system and therefore is able to integrate into many
genomic locations. A major improvement to the system
would be to make the localization or binding of PB to
the genomic target a ‘required’ event for transposition.
This might be achieved by mutating the native PB DBD
domain such that the transposase would be inhibited from
binding off-target sequences and consequently rely on a
user-supplied DBD, such as a custom TALE, for trans-
position. Furthermore, modifications to the dimerization
domain could prevent PB from dimerizing in solution. On
colocalization of both dimers at the genomic target
sequence via attached TALEs, catalytic activity could the-
oretically be restored. Modifications such as these would
be anticipated to not only eliminate off-target integrations
for targeted clones but also increase the total number of
targeted cells due to the limited number of transposons
being prevented from getting ‘soaked up’ by the rest of
the genome. Recently, Li et al. (52) described excision
competent/integration defective transposases with muta-
tions in PB’s catalytic core. Interestingly, the integration
activity of these mutants can be rescued by fusing a
custom zinc-finger DBD to the transposase. However, in-
tegrations were not associated with the recognition sites of
the custom zinc-fingers, as genomic targeting using these
fusion proteins was unsuccessful. Nevertheless, these PB
mutants could potentially serve as a framework for future
studies into site-required transposition.
Targetable nucleases have been used to insert transgenes
into endogenous genes and safe harbor loci in embryonic
and induced pluripotent stem cells (53–58), and easy-to-
implement modifications to both zebrafish and rat
genomes have become a possibility (59,60). One of the
benefits of using transposase-based genomic targeting
over nuclease-based techniques is that integration via the
class II transposon cut-and-paste mechanism is readily
identified by assaying the copy number of transposon in-
sertions. Therefore, a single-insertion clone is not expected
to have additional DNA modifications (35). In compari-
son, because targetable nucleases are capable of mutating
the genome without introducing an identifiable insert, it
remains difficult to confirm the DNA integrity of modified
cells. Genomic screens used to attempt to identify off-
target nuclease mutations are complex and limited in
coverage (23,24,54,57).
The PB system can permanently introduce large cas-
settes (>100 kb) encoding numerous components such as
multiple transgenes, insulators and inducible or endogen-
ous promoters (61). The current study has laid the ground-
work for enhancing this system by allowing researchers to
potentially target integrations to nearly any genomic
region. This system is especially applicable for cell-replace-
ment therapies where safe single-targeted insertions
could be verified ex vivo, and cells could subsequently
be amplified and re-infused into patients. We envision
targeted transposition could be used to intentionally
disrupt endogenous coding regions or to direct insertions
to user-defined genomic safe harbors to protect the cargo
from unknown chromosomal position effects and to cir-
cumvent accidental mutation of target cells.
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